Olena Tsurkalenko
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Olena Tsurkalenko has a total of 142 co-authors. Here are the top co-authors by number of shared publications:
- Anne-Marie Hanff
Transversal Translational Medicine, Luxembourg Institute of Health, Strassen, Luxembourg
2 shared publications Armin Rauschenberger
2 shared publications- Christopher McCrum
Maastricht University
2 shared publications Claire Pauly
2 shared publicationsGelani Zelimkhanov
Luxembourg Centre for Systems Biomedicine (LCSB), University of Luxembourg, Esch-sur-Alzette, Luxembourg
2 shared publications- Gloria A. Aguayo
Department of Precision Health, Luxembourg Institute of Health, Strassen, Luxembourg
2 shared publications
Latest Publications
- Open Access
- 1 March 2026
- Published by AME Publishing Company in AME Case Reports
- Vol. 10, 67
Endovascular management of craniospinal arteriovenous fistula causing steal syndrome in neurofibromatosis type 1: a case report
Background: Neurofibromatosis type 1 (NF1) is an autosomal dominant genetic disorder. It primarily involves cutaneous, neurological and skeletal systems, with vascular involvement being relatively uncommon. Among the reported vascular manifestations, stenoses, aneurysms, and arteriovenous fistulas (AVFs) are infrequent but potentially serious complications. Their manifestation with cerebral steal syndrome is of even lower prevalence. Case Description: We report a case of a 52-year-old female with known NF1 who presented with progressive headache, transient episodes of right-sided weakness and speech problems. Total selective digital subtractive cerebral angiography revealed AVF of the left occipital region, primarily supplied by a large longitudinal defect in the V4 segment of the left vertebral artery, with additional feeders from the left occipital and ascending cervical arteries. A vertebrobasilar “steal” phenomenon was observed, with retrograde filling of the basilar circulation via the carotid system. Given the progressive symptoms and hemodynamic compromise, the patient underwent endovascular embolization using balloon catheters, detachable coils and Onyx 18 liquid embolic agent. The procedure was uneventful, with successful devascularization of the AVF and improved perfusion to the surrounding tissue. Post procedural recovery was favorable, with disappearing of existed symptoms. Conclusions: AVFs are rare in patients with NF1, and their pathogenesis is not fully understood. Steal syndrome occurs when high flow vascular malformations divert blood from surrounding brain parenchyma, leading to ischemic symptoms. Our case contributes to the limited literature on NF1-associated AVF and supports early neurovascular imaging in symptomatic individuals. Awareness of this rare vascular complication in NF1 is crucial for timely diagnosis and management.
- 1 March 2026
- Published by AME Publishing Company in AME Case Reports
- Vol. 10, 67
Open AccessEndovascular management of craniospinal arteriovenous fistula causing steal syndrome in neurofibromatosis type 1: a case report
Background: Neurofibromatosis type 1 (NF1) is an autosomal dominant genetic disorder. It primarily involves cutaneous, neurological and skeletal systems, with vascular involvement being relatively uncommon. Among the reported vascular manifestations, stenoses, aneurysms, and arteriovenous fistulas (AVFs) are infrequent but potentially serious complications. Their manifestation with cerebral steal syndrome is of even lower prevalence. Case Description: We report a case of a 52-year-old female with known NF1 who presented with progressive headache, transient episodes of right-sided weakness and speech problems. Total selective digital subtractive cerebral angiography revealed AVF of the left occipital region, primarily supplied by a large longitudinal defect in the V4 segment of the left vertebral artery, with additional feeders from the left occipital and ascending cervical arteries. A vertebrobasilar “steal” phenomenon was observed, with retrograde filling of the basilar circulation via the carotid system. Given the progressive symptoms and hemodynamic compromise, the patient underwent endovascular embolization using balloon catheters, detachable coils and Onyx 18 liquid embolic agent. The procedure was uneventful, with successful devascularization of the AVF and improved perfusion to the surrounding tissue. Post procedural recovery was favorable, with disappearing of existed symptoms. Conclusions: AVFs are rare in patients with NF1, and their pathogenesis is not fully understood. Steal syndrome occurs when high flow vascular malformations divert blood from surrounding brain parenchyma, leading to ischemic symptoms. Our case contributes to the limited literature on NF1-associated AVF and supports early neurovascular imaging in symptomatic individuals. Awareness of this rare vascular complication in NF1 is crucial for timely diagnosis and management.
- Open Access
- 19 May 2025
- Published by SAGE Publications in Journal of Parkinson’s Disease
- Vol. 15 (4) , 805-818
Sex-specific progression of Parkinson's disease: A longitudinal mixed-models analysis
Background: Despite its relevance, the clinical progression of motor- and non-motor symptoms associated with Parkinson's disease (PD) is poorly described and understood, particularly in relation to sex-specific differences in clinical progression. Objective: Identification of differential aspects in disease progression in men and women with PD. Methods: Linear mixed-model analyses of 802 people with typical PD from the Luxembourg Parkinson's study's prospective cohort (median time of follow-up = three years). We estimated the effect of time and its moderation by sex (alpha ≤ 0.05), including confidence intervals, for the following outcomes: MDS-UPDRS I-IV, Starkstein Apathy Scale, Beck Depression Inventory, Montreal Cognitive Assessment (MoCA), Sniffin’ sticks, bodily discomfort, rapid eye movement sleep behavior disorder questionnaire, PD Sleep Scale (PDSS), Munich Dysphagia Test-PD, Functional Mobility Composite Score, and the MDS-based tremor and postural instability and gait disturbances scale. In addition, the marginal means illustrated the symptoms’ trajectories in men and women. Men and women had similar age. Results: Overall, we observed a slower progression (interaction effect) in women compared to men, especially for MoCA (−0.159, 95%CI [−0.272, −0.046], p = 0.006), PDSS (−0.716, 95%CI [−1.229, −0.203], p = 0.006), PIGD (0.133, 95%CI [0.025 0.241], p = 0.016), and MDS-UPDRS II (0.346, 95%CI [0.120, 0.572], p = 0.003). The finding for MDS-UPDRS II was significant (FWER of 5%) after adjustment for multiple comparisons (Bonferroni-Holm). Conclusions: Next to the further exploration of sex-specific progression, interventions, proactive monitoring and communication strategies tailored to the symptoms progression and needs of men and women need to be developed.
- 19 May 2025
- Published by SAGE Publications in Journal of Parkinson’s Disease
- Vol. 15 (4) , 805-818
Open AccessSex-specific progression of Parkinson's disease: A longitudinal mixed-models analysis
Background: Despite its relevance, the clinical progression of motor- and non-motor symptoms associated with Parkinson's disease (PD) is poorly described and understood, particularly in relation to sex-specific differences in clinical progression. Objective: Identification of differential aspects in disease progression in men and women with PD. Methods: Linear mixed-model analyses of 802 people with typical PD from the Luxembourg Parkinson's study's prospective cohort (median time of follow-up = three years). We estimated the effect of time and its moderation by sex (alpha ≤ 0.05), including confidence intervals, for the following outcomes: MDS-UPDRS I-IV, Starkstein Apathy Scale, Beck Depression Inventory, Montreal Cognitive Assessment (MoCA), Sniffin’ sticks, bodily discomfort, rapid eye movement sleep behavior disorder questionnaire, PD Sleep Scale (PDSS), Munich Dysphagia Test-PD, Functional Mobility Composite Score, and the MDS-based tremor and postural instability and gait disturbances scale. In addition, the marginal means illustrated the symptoms’ trajectories in men and women. Men and women had similar age. Results: Overall, we observed a slower progression (interaction effect) in women compared to men, especially for MoCA (−0.159, 95%CI [−0.272, −0.046], p = 0.006), PDSS (−0.716, 95%CI [−1.229, −0.203], p = 0.006), PIGD (0.133, 95%CI [0.025 0.241], p = 0.016), and MDS-UPDRS II (0.346, 95%CI [0.120, 0.572], p = 0.003). The finding for MDS-UPDRS II was significant (FWER of 5%) after adjustment for multiple comparisons (Bonferroni-Holm). Conclusions: Next to the further exploration of sex-specific progression, interventions, proactive monitoring and communication strategies tailored to the symptoms progression and needs of men and women need to be developed.
- Open Access
- 20 August 2024
- Published by Springer Nature in npj Parkinson's Disease
- Vol. 10 (1) , 1-14
Assessing the clinical utility of inertial sensors for home monitoring in Parkinson’s disease: a comprehensive review
This review screened 296 articles on wearable sensors for home monitoring of people with Parkinson’s Disease within the PubMed Database, from January 2017 to May 2023. A three-level maturity framework was applied for classifying the aims of 59 studies included: demonstrating technical efficacy, diagnostic sensitivity, or clinical utility. As secondary analysis, user experience (usability and patient adherence) was evaluated. The evidences provided by the studies were categorized and stratified according to the level of maturity. Our results indicate that approximately 75% of articles investigated diagnostic sensitivity, i.e. correlation of sensor-data with clinical parameters. Evidence of clinical utility, defined as improvement on health outcomes or clinical decisions after the use of the wearables, was found only in nine papers. A third of the articles included reported evidence of user experience. Future research should focus more on clinical utility, to facilitate the translation of research results within the management of Parkinson’s Disease.
- 20 August 2024
- Published by Springer Nature in npj Parkinson's Disease
- Vol. 10 (1) , 1-14
Open AccessAssessing the clinical utility of inertial sensors for home monitoring in Parkinson’s disease: a comprehensive review
This review screened 296 articles on wearable sensors for home monitoring of people with Parkinson’s Disease within the PubMed Database, from January 2017 to May 2023. A three-level maturity framework was applied for classifying the aims of 59 studies included: demonstrating technical efficacy, diagnostic sensitivity, or clinical utility. As secondary analysis, user experience (usability and patient adherence) was evaluated. The evidences provided by the studies were categorized and stratified according to the level of maturity. Our results indicate that approximately 75% of articles investigated diagnostic sensitivity, i.e. correlation of sensor-data with clinical parameters. Evidence of clinical utility, defined as improvement on health outcomes or clinical decisions after the use of the wearables, was found only in nine papers. A third of the articles included reported evidence of user experience. Future research should focus more on clinical utility, to facilitate the translation of research results within the management of Parkinson’s Disease.
- Open Access
- 19 July 2024
- Published by Center for Open Science in OSF Preprints
Progression of GBA1 Gaucher-related and Parkinson’s-risk variants: A longitudinal mixed model analysis
BACKGROUNDHeterozygous variants in the gene glucocerebrosidase (GBA1) causing Gaucher’s disease, a recessive lysosomal storage disorder, are involved in Parkinson’s disease (PD) pathogenesis. An association of those Gaucher-related GBA1 variants with the progression of non-motor symptoms in PD has been reported but the role of Parkinson’s-risk (PD-risk) GBA1 variants is less clear. Analysis of longitudinal changes in motor- and non-motor symptoms in carriers of the different GBA1 variants compared to non-carriers could elucidate their pathogenic relevance.OBJECTIVESTo compare progression of motor- and non-motor symptoms in people with PD carrying heterozygous Gaucher-related or PD-risk GBA1 variants compared to non-carriers.METHODSWe included longitudinal data of 733 individuals with typical PD. Next to non-carriers, we included 29 carriers of heterozygous Gaucher-related GBA1 variants (22 and 7 carriers of severe and mild variants, respectively) and 47 carriers of heterozygous PD-risk GBA1 variants. A two-level mixed model analysis examined interaction effects of carrying one of the three GBA1 variants (PD-risk, mild or severe) compared to non-carriers with time since diagnosis to estimate gene-variant trajectories of motor- and non-motor symptoms.RESULTSCompared to non-carriers, at nominal 5% significance level, carrying PD-risk or Gaucher-related severe variants was associated with faster cognitive decline with standardized interaction effects of 0.291 (95%CI: 0.014, 0.567, p = 0.039) and 0.614 (95%CI: 0.193, 1.036, p = 0.040), respectively. Carrying PD-risk variants was associated with faster worsening of apathy (0.380, 95%CI: 0.115, 0.645, p = 0.005), quality of sleep (0.244, 95%CI: 0.017, 0.471, p = 0.035), tremor (0.258, 95%CI: 0.001, 0.515, p = 0.050), and non-motor symptoms (MDS-UPDRS I) (0.270, 95%CI: 0.014, 0.526, p = 0.039) compared to non-carriers, while we did not observe this tendency in people with Gaucher-related mild or severe variants. The findings were not significant after Bonferroni-adjustment for 15 outcomes and 3 variants. Finally, we observed an overall slower progression in non-motor symptoms in carriers of mild variants as compared to carriers of PD-risk or severe variants.CONCLUSIONSThe study suggests associations of the PD-risk variants with a more rapid disease progression compared to non-carriers and thus, if findings are confirmed in an independent cohort, advocates for a reevaluation of their pathologic relevance.
- 19 July 2024
- Published by Center for Open Science in OSF Preprints
Open AccessProgression of GBA1 Gaucher-related and Parkinson’s-risk variants: A longitudinal mixed model analysis
BACKGROUNDHeterozygous variants in the gene glucocerebrosidase (GBA1) causing Gaucher’s disease, a recessive lysosomal storage disorder, are involved in Parkinson’s disease (PD) pathogenesis. An association of those Gaucher-related GBA1 variants with the progression of non-motor symptoms in PD has been reported but the role of Parkinson’s-risk (PD-risk) GBA1 variants is less clear. Analysis of longitudinal changes in motor- and non-motor symptoms in carriers of the different GBA1 variants compared to non-carriers could elucidate their pathogenic relevance.OBJECTIVESTo compare progression of motor- and non-motor symptoms in people with PD carrying heterozygous Gaucher-related or PD-risk GBA1 variants compared to non-carriers.METHODSWe included longitudinal data of 733 individuals with typical PD. Next to non-carriers, we included 29 carriers of heterozygous Gaucher-related GBA1 variants (22 and 7 carriers of severe and mild variants, respectively) and 47 carriers of heterozygous PD-risk GBA1 variants. A two-level mixed model analysis examined interaction effects of carrying one of the three GBA1 variants (PD-risk, mild or severe) compared to non-carriers with time since diagnosis to estimate gene-variant trajectories of motor- and non-motor symptoms.RESULTSCompared to non-carriers, at nominal 5% significance level, carrying PD-risk or Gaucher-related severe variants was associated with faster cognitive decline with standardized interaction effects of 0.291 (95%CI: 0.014, 0.567, p = 0.039) and 0.614 (95%CI: 0.193, 1.036, p = 0.040), respectively. Carrying PD-risk variants was associated with faster worsening of apathy (0.380, 95%CI: 0.115, 0.645, p = 0.005), quality of sleep (0.244, 95%CI: 0.017, 0.471, p = 0.035), tremor (0.258, 95%CI: 0.001, 0.515, p = 0.050), and non-motor symptoms (MDS-UPDRS I) (0.270, 95%CI: 0.014, 0.526, p = 0.039) compared to non-carriers, while we did not observe this tendency in people with Gaucher-related mild or severe variants. The findings were not significant after Bonferroni-adjustment for 15 outcomes and 3 variants. Finally, we observed an overall slower progression in non-motor symptoms in carriers of mild variants as compared to carriers of PD-risk or severe variants.CONCLUSIONSThe study suggests associations of the PD-risk variants with a more rapid disease progression compared to non-carriers and thus, if findings are confirmed in an independent cohort, advocates for a reevaluation of their pathologic relevance.
- Open Access
- 4 July 2024
- Published by Elsevier in Parkinsonism & Related Disorders
- Vol. 126
Levodopa-induced dyskinesia in Parkinson's disease: Insights from cross-cohort prognostic analysis using machine learning
- 4 July 2024
- Published by Elsevier in Parkinsonism & Related Disorders
- Vol. 126
Open AccessLevodopa-induced dyskinesia in Parkinson's disease: Insights from cross-cohort prognostic analysis using machine learning
- Open Access
- 24 September 2019
- Published by Communicable Diseases Intensive Care Association in Infusion & Chemotherapy
- No. 2
Perspective Treatment Goals for Brain Protection in Case of Acute Ischemia
Ischemic stroke initiates a cascade of biochemical reactions, among which the processes of free radical oxidation occupy a key place. The most important place in management this disease takes reperfusion therapy, the conduct of which is closely related to the problem of neuroprotection. Use of antioxidants is a promising direction for the treatment of ischemic stroke. They have antioxidant effects and could prevent free radical processes. Edaravone is a new low molecular weight free radical scavenger, which inhibits the ischemic cascade. The article provides an overview of studies on the effectiveness and safety of edaravone in patients with ischemic stroke.
- 24 September 2019
- Published by Communicable Diseases Intensive Care Association in Infusion & Chemotherapy
- No. 2
Open AccessPerspective Treatment Goals for Brain Protection in Case of Acute Ischemia
Ischemic stroke initiates a cascade of biochemical reactions, among which the processes of free radical oxidation occupy a key place. The most important place in management this disease takes reperfusion therapy, the conduct of which is closely related to the problem of neuroprotection. Use of antioxidants is a promising direction for the treatment of ischemic stroke. They have antioxidant effects and could prevent free radical processes. Edaravone is a new low molecular weight free radical scavenger, which inhibits the ischemic cascade. The article provides an overview of studies on the effectiveness and safety of edaravone in patients with ischemic stroke.